Physician profile
Christopher Chapman
NPI 1225044324
$1,183.99
in general payments reported to CMS, 2019-2025
14 companies · $465 in 2025
The $465 reported for 2025 was more than what a typical Ophthalmology provider received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $199 · 2021: $52.96 · 2022: $90.73 · 2023: $214 · 2024: $162 · 2025: $465.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $629 · Education: $212.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $629.49 |
| Education | $212.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Regeneron Healthcare Solutions, INC. | $337.35 | 2023-2025 | Eylea Hd, Eylea |
| Covidien LP | $178.03 | 2019 | |
| Astellas Pharma Global Development | $129.00 | 2025 | Izervay |
| Astellas Pharma US INC | $126.44 | 2025 | Izervay |
| Abbvie INC. | $120.91 | 2022-2025 | Ozurdex |
| Ani Pharmaceuticals, INC. | $90.35 | 2025 | Purified Cortrophin Gel |
| Alcon Vision LLC | $44.86 | 2022 | |
| Genentech USA, INC. | $44.61 | 2023 | Vabysmo |
| Eyepoint US, INC. | $22.90 | 2022 | |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $20.78 | 2019 | |
| Oculus Surgical INC. | $20.38 | 2021 | |
| Allergan, INC. | $19.09 | 2021 | |
| Apellis Pharmaceuticals, INC. | $15.80 | 2025 | Syfovre |
| Beaver-Visitec International, INC. | $13.49 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Christopher Chapman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.